Your browser doesn't support javascript.
loading
Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line.
Shali, Hajar; Shabani, Mahdi; Pourgholi, Fatemeh; Hajivalili, Mahsa; Aghebati-Maleki, Leili; Jadidi-Niaragh, Farhad; Baradaran, Behzad; Movassaghpour Akbari, Ali Akbar; Younesi, Vahid; Yousefi, Mehdi.
Afiliación
  • Shali H; a Tuberculosis and Lung Disease Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
  • Shabani M; b Student's Research Committee , Tabriz University of Medical Sciences , Tabriz , Iran.
  • Pourgholi F; c Department of Immunology, School of Medicine , Shahid Beheshti University of Medical Sciences , Tehran , Iran.
  • Hajivalili M; d Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran.
  • Aghebati-Maleki L; d Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran.
  • Jadidi-Niaragh F; d Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran.
  • Baradaran B; a Tuberculosis and Lung Disease Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
  • Movassaghpour Akbari AA; d Department of Immunology , Tabriz University of Medical Sciences , Tabriz , Iran.
  • Younesi V; e Hematology and Oncology Research Center , Tabriz University of Medical Sciences , Tabriz , Iran.
  • Yousefi M; f Pishtaz Teb Diagnostics , Tehran , Iran.
Artif Cells Nanomed Biotechnol ; 46(2): 293-302, 2018 Mar.
Article en En | MEDLINE | ID: mdl-28362176

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Doxorrubicina / Receptor IGF Tipo 1 / ARN Interferente Pequeño / Quitosano / Nanopartículas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Artif Cells Nanomed Biotechnol Año: 2018 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Doxorrubicina / Receptor IGF Tipo 1 / ARN Interferente Pequeño / Quitosano / Nanopartículas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Artif Cells Nanomed Biotechnol Año: 2018 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido